MedTrace Logo

Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population Part II

NCT00377117 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2018-11-06

No results posted yet for this study

Summary

The purpose of this study is to learn more about the relationship between serious mental illness and the detection and management of diabetes and pre-diabetic conditions. Patients who have been diagnosed with schizophrenia are at an increased risk for developing diabetes and pre-diabetic conditions such as impaired glucose tolerance and impaired fasting glucose. In addition, novel antipsychotics have also been linked to impaired glucose metabolism and increased incidence of diabetes. The medical management of these patients may be difficult ot achieve through standard family practice. The objectives of this project are to: screen a sample of this high-risk population using an Oral Glucose Tolerance Test (OGTT), and to provide multidisciplinary team support to those identified as having diabetes or a pre-diabetic condition.

Conditions

Interventions

PROCEDURE

Management

PROCEDURE

Screening

Sponsors & Collaborators

  • Eli Lilly and Company

    collaborator INDUSTRY

  • St. Joseph's Health Care London

    collaborator OTHER

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Stewart B Harris, MD MPH CCFP FACPM · Centre for Studies in Family Medicine

  • David RS Haslam, MSc MD FRCPC · St. Joseph's Health Care London

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Completion
2007-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00377117 on ClinicalTrials.gov